Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: The pan-HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR-mutated and -wildtype non-small cell lung cancer cells

Fig. 2

Combination treatment with panobinostat and erlotinib shows no increase in cytotoxicity after 72 h. Viability of NSCLC cells after 72 h of treatment with PS and/or erlotinib measured via Trypan blue exclusion assay. No significant induction of cell death was measured. This was also validated by flow cytometry with Annexin V and 7-AAD (data not shown)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us